Yakir Levin is a Dermatology physician affiliated with Harvard University. OpenAlex indexes 19 publications with 872 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
50 Staniford St Ste 250
Boston, MA 021142517
Telephone
617-726-2914Registry record last updated 4 Feb 2019.
Clinical trials
- Tolerability of 532 nm Laser Treatment of Port Wine Stains
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
32.5%Azole Antifungal27.6%Ketoconazole90%Fluconazole11%Part D<11 patientsTetracycline-class Drug5%Doxycycline Monohydrate100%Part D<11 patientsSensory organs
23.4%Corticosteroid23.4%Hydrocortisone38%Clobetasol Propionate36%Betamethasone Dipropionate26%Part D≥23 patientsDermatology
18.9%Corticosteroid12.6%Triamcinolone Acetonide100%Part D≥33 patientsInterleukin-4 Receptor alpha Antagonist3.1%Dupixent Pen100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Barriers to clinical cosmetic and laser dermatology research in the academic setting by source of funding: a systematic review
Archives of Dermatological Research
2025 - Pearls for dermatology resident education in cosmetic and laser procedures
Dermatology Online Journal
2025 - Multidisciplinary Dermatology: A Framework from the Association of Academic Cosmetic Dermatology.
PubMed
2025 - Availability of lasers and hands-on training in cosmetic dermatology in residency
Journal of the American Academy of Dermatology
2024 - Strategies for overcoming obstacles to hands-on cosmetic and laser training in dermatology residency
Journal of the American Academy of Dermatology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”